Author name: Carl Baillargeon

Announcement – Rare Disease Day

CQDM and Neurenati Therapeutics Fund the Development of an Innovative Treatment against Hirschsprung Disease Montreal, February 29, 2024 – On this International Rare Disease Day, CQDM is proud to announce the funding of a collaborative research project aimed to develop a revolutionary therapeutical approach for Hirschsprung disease. This project with a total value of over […]

Announcement – Rare Disease Day Read More »

Development of a Variant-Agnostic COVID-19 Protein Antigen Candidate for a Intranasal Vaccine

Challenge: As the global SARS-CoV-2 situation continues to evolve, the strategy of focusing vaccine development on the currently dominant variant of concern (eg. BA.4 and BA.5 in 2022, XBB.1.5 in 2023) should be complemented by approaches that provide more durable and wider protection against future, emerging variants that can be quickly manufactured for urgent deployment. Solution: The

Development of a Variant-Agnostic COVID-19 Protein Antigen Candidate for a Intranasal Vaccine Read More »

Artificial intelligence-driven nerve identification and decision support-assisted regional anesthesia

Challenge: Nerve blocks have revolutionized anesthesia and surgery as well as chronic pain management. They provide better pain relief, significantly reduce the need for opioids, thus impacting on the problem of opioid addiction, speed up recovery from surgery, as well as shorten hospital stay. However, they require special training as well as regular skills maintenance. Very

Artificial intelligence-driven nerve identification and decision support-assisted regional anesthesia Read More »

Validation of KQ-791 in combination immunotherapies cancer models

Challenge: The knowledge gained in cancer immunology has increased the list of new therapeutic applications. Yet, these approaches (CAR-T, check-point inhibitors and others) are still suffering from several drawbacks, among them: very high cost, more complex biological or/and cellular-based technologies, lack of efficiency against solid tumours, difficulties in validating multiple combination therapies, increased difficulty in selection

Validation of KQ-791 in combination immunotherapies cancer models Read More »

Development of novel immunotherapeutic approaches targeting gene fusion-derived neoantigens to cure pediatric acute leukemia

Challenge: Acute leukemia is the most common blood cancer in children. Aggressive chemotherapy and radiation treatments cure about 80% of affected children. However, they are not perfect cures since a part of children is incurable and dies of leukemia and these treatments kill not only the cancer cells, but also the healthy ones. As a result,

Development of novel immunotherapeutic approaches targeting gene fusion-derived neoantigens to cure pediatric acute leukemia Read More »

Innovative immunotherapy using Chimeric Antigen Receptor (CAR) in hematopoietic stem cells for pediatric acute lymphoblastic leukemia and rhabdomyosarcoma

Challenge: The Chimeric Antibody Receptor (CAR) presents a promising avenue in cancer immunotherapy by engineering patients’ T cells to express CAR molecules, enabling targeted recognition and elimination of tumor cells. While CAR-T therapy has demonstrated notable success in inducing remission for B cell leukemia, lymphoma, and multiple myeloma, it has failed in non-hematologic solid tumors, with

Innovative immunotherapy using Chimeric Antigen Receptor (CAR) in hematopoietic stem cells for pediatric acute lymphoblastic leukemia and rhabdomyosarcoma Read More »

Testing an Accum-Reprogrammed Mesenchymal stromal cell (ARM) melanoma vaccine

Challenge: Vaccination has historically shown effectiveness in preventing morbidity caused by infectious diseases. Therefore, the notion of developing cancer vaccines remains appealing as a combinatory approach with the current standard of care. Unfortunately, a long list of vaccines tested so far has not been successful in achieving the hoped-for clinical outcome. As a result, the past

Testing an Accum-Reprogrammed Mesenchymal stromal cell (ARM) melanoma vaccine Read More »

Development of novel targeted therapies and diagnostic tools for high risk pediatric leukemias

Challenge: Despite improvements in the treatment of many pediatric cancers, high-risk subtypes such as acute myeloid leukemia (AML) and acute megakrayoblastic leukemia (AMKL) still have amongst the worst prognosis, with only ~40-60% survival at 5-years. There is therefore a critical unmet medical need for novel targeted treatments but to completely eradicate the tumor cells these treatments

Development of novel targeted therapies and diagnostic tools for high risk pediatric leukemias Read More »

Research and development of an antimetastatic peptide conjugate of docetaxel (TH1902) against sortilin positive cancers

Challenge: Cancers with metastases are responsible for 90% of cancer deaths. Unfortunately, metastases often become refractory to treatment and although certain molecules are theoretically able to act on these tumors, their non-targeted administration greatly limits their effectiveness. Solution: This project aims to validate the efficacy of the peptide-drug (TH1902) on secondary tumors by characterizing its mechanisms of

Research and development of an antimetastatic peptide conjugate of docetaxel (TH1902) against sortilin positive cancers Read More »

Scroll to Top